NasdaqGS:BEAMBiotechs
Is Beam Therapeutics’ (BEAM) Alpha-1 Update Quietly Reframing the Story of Its Gene-Editing Platform?
In recent days, Beam Therapeutics received a favorable regulatory update for its Alpha-1 Antitrypsin Deficiency program, while Bernstein reiterated a positive stance and ARK Investment Management added 116,000 shares, alongside the company outlining 2026 priorities to advance its genetic medicines pipeline.
An additional development was the open-market sale of 6,198 shares by Senior Vice President Bethany J. Cavanagh under a pre-arranged Rule 10b5-1 trading plan, offering investors a window...